Pericyte-coverage of human tumor vasculature and nanoparticle permeability

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 5, 2012, Pages 761-766

  Zhang, Liuzhe ^a   Nishihara, Hiroshi ^b   Kano, Mitsunobu R ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Desmoplasia; Nano drug delivery system; Pericyte; Refractory tumor; Tumor vasculature

Indexed keywords

CD34 ANTIGEN; NANOPARTICLE; SMOOTH MUSCLE ACTIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER RESEARCH; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; EXTRAVASATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROMORPHOLOGY; MOUSE; NANOANALYSIS; NANOCHEMISTRY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERICYTE; PHENOTYPIC VARIATION; POROSITY; STOMACH CANCER; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PERMEABILITY;

EID: 84861205310     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.761     Document Type: Article

References (35)

1. Gaitanis A, Staal S. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol. Biol., 624, 385-392 (2010).
2. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci., 100, 572-579 (2009).
3. Simpson JK, Miller RF, Spittle MF. Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. Clin. Oncol. (R. Coll. Radiol.), 5, 372-374 (1993).
4. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol., 15, 987-993 (1997).
5. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat. Rev. Cancer, 10, 707-719 (2010).
6. Kano MR, Komuta Y, Iwata C, Oka M, Shirai YT, Morishita Y, Ouchi Y, Kataoka K, Miyazono K. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci., 100, 173-180 (2009).
7. Giroux V, Malicet C, Barthet M, Gironella M, Archange C, Dagorn J-C, Vasseur S, Iovanna JL. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin. Cancer Res., 12, 235-241 (2006).
8. Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Houghton JA, Rutherford PG, Tanzer LR, Boder GB, Grindey GB. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest. New Drugs, 14, 243-247 (1996).
9. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol., 7, 347-353 (1996).
10. Chrastina A, Massey KA, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 3, 421-437 (2011).
11. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst., 98, 335-344 (2006).
12. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, Terada Y, Kano MR, Miyazono K, Uesaka M, Nishiyama N, Kataoka K. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol., 6, 815-823 (2011).
13. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp. Cell Res., 312, 623-629 (2006).
14. Armulik A, Genové G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell, 21, 193-215 (2011).
15. Nisancioglu MH, Betsholtz C, Genové G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res., 70, 5109-5115 (2010).
16. Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasqualini R, Arap W, McDonald DM. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer, 104, 2104-2115 (2005).
17. Sennino B, Falcón BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of plateletderived growth factor B by selective aptamer AX102. Cancer Res., 67, 7358-7367 (2007).
18. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res., 314, 15-23 (2003).
19. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K. Improvement of cancertargeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. U.S.A., 104, 3460-3465 (2007).
20. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer, 6, 392-401 (2006).
21. Sarrazy V, Billet F, Micallef L, Coulomb B, Desmoulière A. Mechanisms of pathological scarring: role of myofibroblasts and current developments. Wound Repair Regen., 19 (Suppl. 1), s10-s15 (2011).
22. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA, Keogh G, Merrett N, Pirola R, Wilson JS. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas, 29, 179-187 (2004).
23. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand., 64, 31-49 (1965).
24. Wu C-W, Chi C-W Lin W-C. Gastric cancer: prognostic and diagnostic advances. Expert Rev. Mol. Med., 4, 1-12 (2004).
25. Ikeguchi M, Miyake T, Matsunaga T, Yamamoto M, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S, Tsujitani S. Recent results of therapy for scirrhous gastric cancer. Surg. Today, 39, 290-294 (2009).
26. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62 (2005).
27. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 156, 1363-1380 (2000).
28. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 65, 271-284 (2000).
29. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest., 112, 1142-1151 (2003).
30. Watsky MA, Weber KT, Sun Y, Postlethwaite A. New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies. Int. Rev. Cell. Mol. Biol., 282, 165-192 (2010).
31. Miyata K, Oba M, Kano MR, Fukushima S, Vachutinsky Y, Han M, Koyama H, Miyazono K, Nishiyama N, Kataoka K. Polyplex micelles from triblock copolymers composed of tandemly aligned segments with biocompatible, endosomal escaping, and DNA-condensing functions for systemic gene delivery to pancreatic tumor tissue. Pharm. Res., 25, 2924-2936 (2008).
32. Kumagai M, Kano MR, Morishita Y, Ota M, Imai Y, Nishiyama N, Sekino M, Ueno S, Miyazono K, Kataoka K. Enhanced magnetic resonance imaging of experimental pancreatic tumor in vivo by block copolymer-coated magnetite nanoparticles with TGF-beta inhibitor. J. Control. Release, 140, 306-311 (2009).
33. Weinberg RA. The Biology of Cancer. 850 (2006).
34. Cao Y. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug? Int. J. Dev. Biol., 55, 557-562 (2011).
35. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov., 10, 417-427 (2011).